{"name":"RXi Pharmaceuticals, Corp.","slug":"rxi-pharmaceuticals-corp","ticker":"","exchange":"","domain":"","description":"RXi Pharmaceuticals, Corp. is a biotechnology company focused on the discovery and development of innovative RNAi-based therapeutics. The company's pipeline includes three drugs in phase 2 clinical trials, targeting various unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":15674000,"netIncome":-26863000,"cash":78345000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxOcWdtWlF4SU1sUzlOOXlKU2g1Yjh6YlYzS0ZYSlFuZHhubDhYd19Cc0V2NUFEcXlSeURLbkVzSHBSaWFEWFRKVnJKbFpkby1pa3VGR3k3UHlnOF9Gd1NlTk55WmlsQ0FMLTU4ZWNkUmF0azVRVGJYTnlaQ2g4bFFVeVI3djFZWXBNZ1BMT0MwTlVfdUZMeEZ6SW1pak1udWFHUldYLU9pemh2b0YxSGttRnBoZnd6SU9TOVl1cjAwcHRSaDRxSEQzaVBmVnFNdDFQMzhFRVNrOU9ONEdLTHB6ZDE3aGtqNTNRdF8tYXJYNWQ4cnRCVTR2cUtfa0IxVDZWa3FRa0h0UFUxMVJ5bFF0aVYybjNzb29nTWJISVEyU1g3aVhzSjRQNlV1cjJkV2FKRmd3TVVmR24wWjRrWUxOLXh6X1NqUmVMUUNIZFFxdEJTZ1ZoZmN6TFRVaWN3U0huc2tNdQ?oc=5","date":"2024-03-13","type":"deal","source":"Business Wire","summary":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com - Busin","headline":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxPbHBVMVczUzl3ZExNekUzSlBJQ1g0bks3V01NblVNYXRCdERibkdkbHMzbTRZSjE1U3M1TV9uWmJWRlo3ZDdUcUJhVkUzRTBhb1FrM1VrUEZJT3Vvd1AtTmpGODlwSC1JMV9MWEtYSEhZNFpTOG4tNW4tWmxVZVpneklFVlRFdmhoN2o2UGZGUEJNM2oyS0xsMnRfUzRTSVVxWHpWbEtGMVg1bGVON1pGMkJOZEp5MV9NcEZYTEJoVHZJUERrUW02azVNeGs4dGZWNnVLQzlpZ0NHaXBnMmZqVHc5M0dEczRCRVBxT0l1OWNOdU4tZXJrYUU1U2ozSzZLRmlzZXVTUWxNUzQ0Z0NfZ1VpaVc4SHNCZ3RubDY1QnZVekhKSV9MRzBNVDBsT083?oc=5","date":"2021-05-12","type":"pipeline","source":"GlobeNewswire","summary":"CloudMD Closes Acquisition of Rxi, Providing an Established - GlobeNewswire","headline":"CloudMD Closes Acquisition of Rxi, Providing an Established","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOSUxIbnBELTVrRjVNUHhIRGdXVnFHNkhKbko1Xzl3cWpOSFZqNS1RYzhLdXAtQU5kS0VMUGwxZkNTVUw3UmFzSVAwcHZhQzRRN1JUQ2UtVmk4Y3dtNG5hSzNoOVVEa0x6d2pJbldaLU5qYmpmVFNRY3BmTF9rM2VvSDQ1dFhjYTZpRGp1ZDg3UGhWaG5vblFHMkNJMF9JeF9ETWxubS0zVWl4S2tIbEJ3eGtZaVFJNWU2Q1ZNRHVCekhPM0w3SzRWTXVicndoTVVfc0VKVVVoYXBzMTZkbEpmVmFzdHIyR0dnNWVvbEp1VElUOUVEVDdhdzJfSVplajc4UHdfenhMbS1jTEppME91MlNqclVXdkhYek1HeXhtV29CcTJxZTJsaF8weFR5WWszMmhzYzVUOWc1bjdnTVA3cjBGV1pycGRJQWFKYUZqYWFyQVdGeXZZ?oc=5","date":"2021-01-26","type":"deal","source":"GlobeNewswire","summary":"CloudMD to Acquire Rxi Group of Companies, an Established - GlobeNewswire","headline":"CloudMD to Acquire Rxi Group of Companies, an Established","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9NeGh6SmFITXpMa2htVUdndHRBSjZ3QW85ZXVydDQ4Ykw5V0Nqd0JNMmZENldCQ2JBRm1NTUpHRWQ0THppazVMX2hSSDVTN0pGMEdJTWJPYldlUlNoMGlLSUNsNmMtXzBVaXI4TVFJZ2J6UVVXcDhF?oc=5","date":"2019-02-15","type":"pipeline","source":"Worcester Business Journal","summary":"Phio Pharma CEO Cauwenbergh to retire - Worcester Business Journal","headline":"Phio Pharma CEO Cauwenbergh to retire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNcVlKQ2QtUHQ5MlJ4Q1VWdUdNaFVlcEVxMWZNMHJINHMzbXFtakVVeHhmdW1RN0VHai1pOTRDbFRpcVBVcXJ1aHptMkFMcFFldHZzcFl3YmJvRXJQSTVOOXptbFFRN21fTUdVNkozeGxDX2tFLVNRS0J6eE1kNjdjVG93?oc=5","date":"2018-12-17","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 10 RNA-Based Biopharmas of 2018 - Genetic Engineering and Biotechnology News","headline":"Top 10 RNA-Based Biopharmas of 2018","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQUEJDVFozdkFmT0pnVllBTjFDd1BfbmxxaEc1V2Z1c0FSOXViZ0phajF2WGZmdEZtU2VpQUFfNmV6U01pbkZqeVNJeWt1R0VNZk5LOERiTUR1WWppZFpvX21BVVJhVW92bjVHcVBSdDdfOExrbWhUb0VaMzh0cThzQnFKb1NVd0RueWNNU1VRYWM0LTdZ?oc=5","date":"2018-11-14","type":"pipeline","source":"Worcester Business Journal","summary":"RXi Pharmaceuticals to change name as it eyes cancer market - Worcester Business Journal","headline":"RXi Pharmaceuticals to change name as it eyes cancer market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQRjhkcGdBTXRYVzhOUFl3YUY5SFBxaGl2SjF2M0FEaHo0T1kwN19qRlBCUXhiWXRlUW9OZ0IyLTVESUZ0UVUyV3VFRUF5WTg1V2loMGNyVi1hc1VJMTVOUWMyYmhvbGhxQmNwT3ZZNkR4MzY2M3BySzUzMGpoVkNweE1OTkg?oc=5","date":"2018-05-29","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Cancer Immunotherapy and RNA Interference - Genetic Engineering and Biotechnology News","headline":"Cancer Immunotherapy and RNA Interference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPN2JjUVFWVVRqeGxVclh5MUt1VXg0TWpyQ3BUN2JPa2E0eGpRb3FtU3VDdGZ4VFdpNmJ6VlktYlczZEVtWDJWeUNmS3N5WThkMUEyMUdTUl9OWVJvRDFFSjNxdlFWdnNHbUtGTjM3VFpPMXhiSUxVTXctcTVWY1ljbm9Fa1pyS0pXbHB0OVZMUVNPSWFFVm9fR2ljTWU0OEZGa2tDSzZ4cjRkaHM?oc=5","date":"2018-03-02","type":"pipeline","source":"Zacks Small Cap Research","summary":"RXII: Exploiting a Natural Mechanism: RXi’s sd-rxRNA - Zacks Small Cap Research","headline":"RXII: Exploiting a Natural Mechanism: RXi’s sd-rxRNA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQcTZtU3d0T2NpWnZrX21MZWtOSmp6Q2hmdGpSZWZYbzVWVFR1TEVic0V3dV9FaUgybkJMM2R3d1JWSkpVQ05saHhKNEtTc2lvSDc3aE5pR1o3STBkdnFOdU4tQXFqQ1h0elJVd1lzdFFHU1dFSklHVk9zVU5wbVRSTEtlY1BDOE1BV3JqRlJTUmJEZjRxUml3eUxMaUF6dw?oc=5","date":"2017-04-07","type":"pipeline","source":"Life Science Leader","summary":"Leading Business With Science: Geert Cauwenbergh of RXi - Life Science Leader","headline":"Leading Business With Science: Geert Cauwenbergh of RXi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOQld2aXRJMl9BQkg2RFFleVRNU3F0WGpJeGhvN2VFWGtBS3JSUzhOLTQteV9ieWp0ak40NkNkNDE0UFcyTDE3UG0yRDdFMnlsRHdnSy1nbHR2b0FPXzJnMzI4MldJalhILXljWWJ6ZEZaZ3hpRlBCcFdPMmZ5TkdVb1gzcFhKSUg1Z3kwN1pHcS00d2tkYlJRU0ktUUFvdGk5Rkh1Wk00MGRyWURGR0JSdjh5ZlhsX0tHcUE?oc=5","date":"2017-02-14","type":"pipeline","source":"BioSpace","summary":"RXi Pharma Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board - BioSpace","headline":"RXi Pharma Appoints Medical Oncology Expert, Dr. James Griffin, To Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPdXlxakpQTWF6RkpZUXNBNkJ4X1hkRWx6azBBamFzV3BiclVSMDRlREF2REdZWlRzZUh2dS1VT0g5NlBrZkZDUmJIazhIdm1PeWhyWVVHWDlNUkdxak02eHFSX3hJdzRjbjU3eU1VdVhZcVJmRmUxNG9LSjM0aUJUQXFzOFl0QmJoVkhyOHUtVUpqYUEzdi1KLUdGTkVwNEFpUmVqcDRrS0FiV3NVSHdnZm9CZDBaemZXZ20xMFZ2bHVFeDRRVlM1YTlJMlFtV013Q2ZxRi0yT003VWl1RHZIQkRYODhMNUI1SVFLR2VDUzhCcHM1RjNn?oc=5","date":"2016-10-17","type":"pipeline","source":"Worcester Telegram","summary":"Ten years on, the search for RNAi-related treatments continues - Worcester Telegram","headline":"Ten years on, the search for RNAi-related treatments continues","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":0,"period":"2023-12-31"},{"value":1000000,"period":"2022-12-31"},{"value":1000000,"period":"2022-12-31"},{"value":7600000,"period":"2021-12-31"},{"value":7600000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15674000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26863000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":78345000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}